# US 2018/0339961 A1 · Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0339961 A1
- Document ID: US20180339961A1
- Status: Published application
- Kind: A1
- Application number: 15/987,274
- Filed: 2018-05-23
- Published: 2018-11-29
- Earliest claimed: 2017-05-23
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: James Varani; Hollis Showalter; Andy White; Kent J. Johnson
- Web page: https://patentgrep.com/patent/US20180339961A1

## CPC

- C07C 235/30: the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 35/02: specific for leukemia
- C07C 233/31: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 233/50: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
- C07D 207/24: Oxygen or sulfur atoms
- C07D 209/54: Spiro-condensed
- C07D 211/74: Oxygen atoms
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07C 2601/02: with a three-membered ring
- C07C 2601/16: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a dimethyl-nonatetraenyl-trimethyl-cyclohexyl structure useful as therapeutics for the treatment of subjects suffering from disorders characterized by abnormal proliferation and/or abnormal differentiation of cells, in particular of cells of which the growth and differentiation is sensitive to the actions of retinoids.

## Claims

### Claim 1

A compound having Formula I:
or a pharmacologically acceptable salt, or a hydrate, or a solvate, or prodrug, thereof; wherein
R1 is CH3, CF3, or is a straight or branched carbon chain of 1-10 carbon atoms, which can contain up to two double or triple bonds, as allowed by valency, and can be optionally substituted with up to three substituents;
R2 is CH3, CF3, or is a straight or branched carbon chain of 1-10 carbon atoms, which can contain up to two double or triple bonds, as allowed by valency, which can be optionally substituted with up to three substituents;
or R2 is CH2(CO)R3;
or R1 and R2, along with the nitrogen both are bonded to can form a ring having 4-7 atoms, optionally substituted with up to three groups chosen independently C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, all of which may be straight chain or branched C3-10 cycloalkyl, C2-5 spiroalkyl, halogen, cyano, oxo, CF3 or OR3, such that when R3 is bonded directly to oxygen, it is R4;
R3 is C2-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, all of which may be straight chain or branched, phenyl, monocyclic or bicyclic 5-10 membered heteroaryl containing up to four heteroatoms chosen from N, O and S, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, optionally substituted with up to three groups chosen independently from C1-10 alkyl, C3-10 cycloalkyl, C2-10 alkenyl C3-10 cycloalkenyl, C2-10 alkynyl, C3-10 branched alkyl, C3-10 branched alkenyl, C4-10 branched alkynyl, C2-5 spiroalkyl, halogen, hydroxy, carboxy, cyano, oxo, or CF3;
R4 is C1-4 lower alkyl straight chain or branched, C3-4, alkenyl straight chain or branched, C3-4 alkynyl, C2-4 lower acyl, CF3 or C2 fluoroalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the up to three substituents are independently chosen from, C3-8 cycloalkyl, C4-8 cycloalkenyl, halo, CN, N3, CF3, NO2, cycloalkyl, substituted cycloalkyl, cycloalkenyl substituted cycloalkenyl, heterocycloalkyl, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, hydroxy, oxo, thio, thiono, amino, cyano, C1-6 alkoxy, C3-6 cycloalkoxy, C1-6alkylthio, C3-6 cycloalkylthio, C1-6 alkylsulfonyl, C3-6 cycloalkylsylfonyl, monoalkylamino, dialkylamino, monocycloalkylamino, bis(cycloalkyl)amino.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R1 is CH3, CF3, C2-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, all of which may be straight chain or branched, or CF3, which can be optionally substituted with up to three groups chosen independently from C1-10 alkyl, C3-10 cycloalkyl, C2-10 alkenyl C3-10 cycloalkenyl, C2-10 alkynyl, wherein all aliphatics may be straight chain or branched, halogen, hydroxy, cyano, oxo, CF3 or OR3, such that when R3 is bonded directly to oxygen, it is R4; and independently
R2 is CH2(CO)R3, C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, all of which may be straight chain or branched, or CF3, which can be optionally substituted with up to three groups chosen independently from C1-10 alkyl, C3-10 cycloalkyl, C2-10 alkenyl C3-10 cycloalkenyl, C2-10 alkynyl, wherein all aliphatics may be straight chain or branched, halogen, hydroxy, cyano, oxo, CF3 or OR3, such that when R3 is bonded directly to oxygen, it is R4.

### Claim 4 (depends on 3)

The compound of any one of claim 3, wherein R4 is C1-4 alkyl.

### Claim 5 (depends on 1)

The compound according to any one of claim 1, wherein R1 and R2, along with the nitrogen both are bonded to can form a ring having 4-7 atoms, optionally substituted with up to three groups chosen independently C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, all of which may be straight chain or branched C3-10 cycloalkyl, C2-5 spiroalkyl, halogen, cyano, oxo, CF3 or OR3, such that when R3 is bonded directly to oxygen, it is R4.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the optionally substituted ring having from 4-7 atoms is selected from the group consisting of:

### Claim 7 (depends on 1)

The compound according to claim 1, wherein OR3, such that when R3 is bonded directly to oxygen it is R4, and R4 is selected from the group consisting of:

### Claim 8 (depends on 3)

The compound according to claim 3, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, or solvate, or hydrate or prodrug.

### Claim 9 (depends on 1)

The compound according to claim 1, in combination with a pharmaceutically acceptable composition.

### Claim 10 (depends on 9)

A method of treating, ameliorating, or preventing disorders characterized by abnormal proliferation and/or abnormal differentiation of cells in a patient comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 9,
wherein said disorder is an oncological disorder or a dermatological disorder,
wherein said patient is a human patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the oncological disorder is selected from group consisting of acute promyelocytic leukemia (APL), neuroblastoma, head- and neck cancer, lung cancer, breast cancer, uterine cervix cancer, gastrointestinal tract cancer, skin cancer, bladder cancer and prostate cancer and similar disorders.

### Claim 12 (depends on 11)

The method of claim 11, wherein the oncological disorder is APL or neuroblastoma.

### Claim 13 (depends on 11)

The method of claim 11, further comprising administering a second drug to said patient, wherein the second drug is one or more anticancer agents, wherein said anticancer agent is a chemotherapeutic agent or a radiation therapy or both.

### Claim 14 (depends on 10)

The method of claim 10, wherein the dermatological disorder is selected from the group consisting of keratinization disorders such as rosacea, acne, psoriasis, severe psoriasis, lamellar ichthyosis, plantar warts, callosities, acanthosis nigricans, lichen planus, molluscum, melasma, corneal epithelial abrasion, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, melasma, hyperpigmentation, skin damage (e.g., skin made atrophic by aging, photodamaged skin, skin damage related to metabolic diseases (e.g., diabetes, skin damage related to steroid use), pressure ulcers/bedsores, and diabetic ulcers.

### Claim 15 (depends on 14)

The method of claim 14 wherein the dermatological disorder is acne.

### Claim 16 (depends on 14)

The method of claim 14 wherein the dermatological disorder is pressure ulcers/bedsores.

### Claim 17 (depends on 14)

The method of claim 14 wherein the dermatological disorder is diabetic ulcers.

### Claim 18 (depends on 14)

The method of claim 14 wherein the dermatological disorder is skin made atrophic by aging.

### Claim 19 (depends on 1)

A kit comprising a compound of claim 1 and instructions for administering said compound to a patient having an oncological disorder and/or a dermatological disorder,
wherein the oncological disorder is selected from group consisting of acute promyelocytic leukemia (APL), neuroblastoma, head- and neck cancer, lung cancer, breast cancer, uterine cervix cancer, gastrointestinal tract cancer, skin cancer, bladder cancer and prostate cancer and similar disorders,
wherein the dermatological disorder is selected from the group consisting of keratinization disorders such as rosacea, acne, psoriasis, severe psoriasis, lamellar ichthyosis, plantar warts, callosities, acanthosis nigricans, lichen planus, molluscum, melasma, corneal epithelial abrasion, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, melasma, hyperpigmentation and similar disorders.

### Claim 20 (depends on 19)

The kit of claim 19, further comprising one or more anticancer agents.
